HIV Protease Inhibitors
"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
Descriptor ID |
D017320
|
MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 | 2000 | 2 | 1 | 3 | 2001 | 1 | 1 | 2 | 2002 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 2004 | 1 | 1 | 2 | 2005 | 0 | 1 | 1 | 2006 | 1 | 2 | 3 | 2007 | 3 | 1 | 4 | 2008 | 2 | 2 | 4 | 2009 | 2 | 0 | 2 | 2010 | 2 | 0 | 2 | 2011 | 3 | 0 | 3 | 2012 | 1 | 0 | 1 | 2013 | 0 | 1 | 1 | 2014 | 1 | 0 | 1 | 2015 | 1 | 0 | 1 | 2016 | 1 | 1 | 2 | 2017 | 1 | 1 | 2 | 2019 | 3 | 0 | 3 | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
Kousari A, Moser C, Olefsky M, Brown TT, Currier JS, McComsey GA, Scherzinger A, Stein JH, Lake JE, Erlandson KM. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. J Acquir Immune Defic Syndr. 2021 12 01; 88(4):399-405.
-
Weinberg A, Huo Y, Kacanek D, Patel K, Watts DH, Wara D, Hoffman RM, Klawitter J, Christians U. Brief Report: Markers of Spontaneous Preterm Delivery in Women Living With HIV: Relationship With Protease Inhibitors and Vitamin D. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):181-187.
-
Huang L, Li L, Tien C, LaBarbera DV, Chen C. Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment. Sci Rep. 2019 01 22; 9(1):301.
-
Hawkins KL, Montague BT, Rowan SE, Beum R, McLees MP, Johnson S, Gardner EM. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals. Antivir Ther. 2019; 24(7):513-519.
-
Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M, McFarland EJ, Van Dyke RB, Jacobson D. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 03; 19(3):175-183.
-
Pinto-Cardoso S, Lozupone C, Brice?o O, Alva-Hern?ndez S, T?llez N, Adriana A, Murakami-Ogasawara A, Reyes-Ter?n G. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens. Sci Rep. 2017 03 06; 7:43741.
-
Smith C, Weinberg A, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ. Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infect Dis Obstet Gynecol. 2016; 2016:9848041.
-
Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18.
-
Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015 Apr; 59(4):2094-101.
-
Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|